HK1081880A1 - Alpha 2b or 2b/2c adrenoceptor agonists for the treatment of neurodegeneration - Google Patents

Alpha 2b or 2b/2c adrenoceptor agonists for the treatment of neurodegeneration

Info

Publication number
HK1081880A1
HK1081880A1 HK06104018.4A HK06104018A HK1081880A1 HK 1081880 A1 HK1081880 A1 HK 1081880A1 HK 06104018 A HK06104018 A HK 06104018A HK 1081880 A1 HK1081880 A1 HK 1081880A1
Authority
HK
Hong Kong
Prior art keywords
alpha
neurodegeneration
treatment
adrenoceptor agonists
disease
Prior art date
Application number
HK06104018.4A
Other languages
English (en)
Inventor
Larry A Wheeler
Daniel W Gil
John E Donello
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of HK1081880A1 publication Critical patent/HK1081880A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK06104018.4A 2002-10-08 2006-03-31 Alpha 2b or 2b/2c adrenoceptor agonists for the treatment of neurodegeneration HK1081880A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41704902P 2002-10-08 2002-10-08
PCT/US2003/031809 WO2004032913A1 (en) 2002-10-08 2003-10-07 Alpha 2b 0r 2b/2c adrenoceptor agonists for the treatment of neurodegeneration

Publications (1)

Publication Number Publication Date
HK1081880A1 true HK1081880A1 (en) 2006-05-26

Family

ID=32093954

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06104018.4A HK1081880A1 (en) 2002-10-08 2006-03-31 Alpha 2b or 2b/2c adrenoceptor agonists for the treatment of neurodegeneration

Country Status (20)

Country Link
US (1) US20040138312A1 (xx)
EP (1) EP1549305B1 (xx)
JP (2) JP4724421B2 (xx)
KR (1) KR20050050124A (xx)
CN (1) CN100431536C (xx)
AT (1) ATE429216T1 (xx)
AU (2) AU2003282758A1 (xx)
BR (1) BR0314540A (xx)
CA (1) CA2501347A1 (xx)
DE (1) DE60327335D1 (xx)
ES (1) ES2322954T3 (xx)
HK (1) HK1081880A1 (xx)
IL (1) IL167849A (xx)
MX (1) MXPA05003664A (xx)
NO (1) NO20051663L (xx)
NZ (1) NZ539328A (xx)
PL (1) PL216373B1 (xx)
RU (1) RU2330649C2 (xx)
WO (1) WO2004032913A1 (xx)
ZA (1) ZA200502744B (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2007206A4 (en) * 2006-03-16 2010-12-08 Yeda Res & Dev METHOD AND COMPOSITION FOR THE PROTECTION OF NEURONAL TISSUE FROM DEGATES INDUCED BY HIGH LEVELS OF GLUTAMATE
WO2009052075A2 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Method of treating motor disorders with alpha-2b adrenergic receptor agonists
US20100216857A1 (en) * 2007-10-18 2010-08-26 Luhrs Lauren M B Method of treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione
WO2009052073A2 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
JP5705742B2 (ja) * 2008-12-08 2015-04-22 アラーガン インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ アルファ２ｂまたはアルファ２ｂおよびアルファ２ｃアドレノセプターのサブタイプ選択性モジュレーターとしてのｎ‐（１‐フェニル‐２‐アリールエチル）‐４，５‐ジヒドロ‐３ｈ‐ピロール‐２‐アミン化合物
EP4371554A2 (en) 2016-12-31 2024-05-22 BioXcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
CN114983980A (zh) 2018-06-27 2022-09-02 比奥克斯塞尔医疗股份有限公司 含右美托咪定的膜制剂及其制造方法
BR112022000992A2 (pt) 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029792A (en) * 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US5210076A (en) * 1988-09-13 1993-05-11 Berliner David L Methods of treating Parkinson's disease using melanin
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US6329369B1 (en) * 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
EP1413576A3 (en) * 1997-12-04 2004-09-01 Allergan, Inc. Substituted imidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors
US6313172B1 (en) * 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
IL151530A0 (en) * 2000-07-14 2003-04-10 Allergan Sales Inc Compositions containing alpha-2-adrenergic agonist components
AU2002248284A1 (en) * 2000-11-01 2002-08-06 Allergan, Inc. Compositions for treatment of ocular neovascularization
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds

Also Published As

Publication number Publication date
US20040138312A1 (en) 2004-07-15
BR0314540A (pt) 2005-07-26
JP2006504739A (ja) 2006-02-09
DE60327335D1 (de) 2009-06-04
CA2501347A1 (en) 2004-04-22
CN100431536C (zh) 2008-11-12
PL376346A1 (en) 2005-12-27
JP4724421B2 (ja) 2011-07-13
AU2009238370B2 (en) 2011-07-21
MXPA05003664A (es) 2005-06-08
PL216373B1 (pl) 2014-03-31
NZ539328A (en) 2007-01-26
AU2003282758A1 (en) 2004-05-04
AU2009238370A1 (en) 2009-12-17
ATE429216T1 (de) 2009-05-15
IL167849A (en) 2011-04-28
CN1703213A (zh) 2005-11-30
EP1549305B1 (en) 2009-04-22
WO2004032913A1 (en) 2004-04-22
ES2322954T3 (es) 2009-07-02
NO20051663L (no) 2005-05-31
RU2005114504A (ru) 2005-10-27
ZA200502744B (en) 2006-02-22
JP2011057700A (ja) 2011-03-24
RU2330649C2 (ru) 2008-08-10
EP1549305A1 (en) 2005-07-06
KR20050050124A (ko) 2005-05-27

Similar Documents

Publication Publication Date Title
HK1081880A1 (en) Alpha 2b or 2b/2c adrenoceptor agonists for the treatment of neurodegeneration
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
IL186200A (en) Use of amylin and agonists, analogues and derivatives of amylin for the preparation of a drug for the treatment of psychiatric illness
PL2026803T3 (pl) Kompozycje R(+) i S(-) pramipeksolu i sposoby ich zastosowania
IL175714A0 (en) Quinazolinone compounds as anticancer agents
MXPA02001306A (es) Composiciones farmaceuticas para el tratamiento de enfermedades del sistema nervioso central y otras enfermedades.
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
PL1656346T3 (pl) 1,2,3,4-Tetrapodstawiony indol do leczenia chorób dróg oddechowych
WO2003092580A3 (en) Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
MXPA04001187A (es) Receptores de interleucina-1 en el tratamiento de enfermedades.
UA96115C2 (uk) Спосіб і композиція для лікування амілоїдогенних захворювань
WO2004009590A8 (de) 4-aminosubstituierte pyrimidinderivate
SI1594833T1 (sl) Derivati 1-fenilalkankarboksilne kisline za zdravljenje nevrodegenerativnih bolezni
WO2004006859A3 (en) Platinum compound
MXPA04000886A (es) Derivados de triazolil-imidazopiridina y triazolilpurinas empledos como ligandos del receptor de adenosina a2a y su uso como medicamentos.
IL178261A0 (en) Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
HK1051324A1 (en) Methods and compositions for modulating alpha adrenergic receptor activity.
WO2003015713A3 (en) Treatment of glial tumors with glutamate antagonists
ZA200201788B (en) Substituted 1,5-dihydropyrrol-2-on derivatives as NMDA receptor antagonists for the treatment of pain.
SE0002934D0 (sv) New aporphine esters and in their use in therapy
MXPA05013151A (es) 3-fluoro-piperidinas como antagonistas de n-metil-d-aspartato/nr2b.
HK1080408A1 (en) Use of brimonidine in the treatment of dementia a nd parkinson
ZA200609220B (en) Method of treating dry eye disorders and uveitis
YU89103A (sh) Novi postupak lečenja opsesivno-kompulsivnog poremećaja (okp) i poremećaja povezanih sa okp-om, korišćenjem gvg-a
WO2003072572A8 (en) Beta3-adrenergic receptor agonists

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20151007